Friday, Sep 3, 1993
South San Francisco, Calif. -- September 3, 1993 --Genentech, Inc. today announced that its pioneer clot-busting drug, Activase® (Alteplase, recombinant) t-PA reached 66 percent marketshare in July. Activase marketshare has been climbing steadily since announcement on April 30, 1993 of the findings of a major new clinical study GUSTO (Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries). The GUSTO findings were published yesterday in the New England Journal of Medicine.
"The strength of the GUSTO data presented on April 30th of this year has increased Activase marketshare from roughly 50 percent to 66 percent in July, which means in three months Activase has already regained its lost marketshare from more than two years ago," emphasized G. Kirk Raab, president and chief executive officer of Genentech. "We plan to submit a t-PA labeling amendment later this Fall consistent with the front-loaded dosing regimen used in the GUSTO study," Raab added.
"Sales of Activase are very strong compared to the same period last year, and we expect yesterday's peer-reviewed article in the New England Journal of Medicine to further communicate the findings throughout the practicing medical community."
Concerning the higher cost of Activase compared to streptokinase, Raab explained that: "The additional benefits derived from Activase have stood up to rigorous cost-effectiveness analysis and have proven to be consistent with the benefits derived from other widely accepted life-saving medical treatments. Also, since Activase was introduced more than five years ago, Genentech has made the drug available free-of charge to patients who cannot afford it and who do not have health insurance."
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.
# # #